AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02841228 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT + SIB + Chemotherapy
Description: For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
Study NCT03355313 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level Light therapy
Description: Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
Study NCT00648089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
Study NCT04157504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical function assessment
Description: Physical function assessment is a tool to evaluate mobility levels of patients
Study NCT02627222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pro-vitamin A biofortified cassava
Description: Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
Study NCT02627222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White cassava
Description: Conventional white cassava
Study NCT01423812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily combination Darunavir and ritonavir
Description: Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily
Study NCT01423812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily combination Darunavir and ritonavir
Description: Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
Study NCT02700243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
Study NCT03366493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FRD
Description: The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
Study NCT03366493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology
Description: Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
Study NCT03366493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
Study NCT03366493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
Study NCT03366493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECC
Description: If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
Study NCT03366493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospy
Description: According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review.
Study NCT03945006 — intervention group
Intervention type: OTHER
Intervention: Incontinence Severity
Description: The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
Study NCT03945006 — intervention group
Intervention type: OTHER
Intervention: Balance
Description: The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
Study NCT03945006 — intervention group
Intervention type: OTHER
Intervention: Trunk impairment
Description: Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
Study NCT03945006 — intervention group
Intervention type: OTHER
Intervention: Fear of falling
Description: Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
Study NCT01978795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain 101 website
Description: Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
Study NCT01978795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
Study NCT00596934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: 0.1 mg/kg/day once a day via subcutaneous injections
Study NCT01690897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment
Description: The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
Study NCT01690897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sex therapy, education, and support treatment
Description: The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
Study NCT04065776 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal-avoidance proton therapy
Description: Hippocampal-avoidance proton therapy
Study NCT03878472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
Study NCT03878472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
Study NCT03878472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
Study NCT03878472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
Study NCT03001128 — intervention group
Intervention type: DRUG
Intervention: Antiretroviral treatment pause
Description: Antiretroviral treatment pause
Study NCT04341896 — intervention group
Intervention type: OTHER
Intervention: Caregivers
Description: Individuals who cared for themselves and their transplant recipient before and after kidney donation
Study NCT04341896 — intervention group
Intervention type: OTHER
Intervention: Non-caregivers
Description: Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
Study NCT01309230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
Study NCT04011228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: After a fasting period over night blood samples will be taken.
Study NCT04011228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and blood samples
Description: After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
Study NCT04011228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
Study NCT02308007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole
Study NCT02308007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Study NCT02308007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole/metronidazole
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10mg would be given morning of surgery as a prokinetic premedication for all patients.
Study NCT01660724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided arterial puncture
Description: Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
Study NCT01660724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arterial puncture technique
Description: Arterial puncture is performed using the conventional technique
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
Study NCT02751723 — intervention group
Intervention type: OTHER
Intervention: validated questionnaires
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: 25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
Study NCT02441673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Would be used for all patients following delivery of the baby to aid contraction of the uterus.
Study NCT03354442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Fixed Mandibular Retractor Appliance
Description: All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
Study NCT02344433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VICKY
Description: Relational agent/virtual counselor
Study NCT02344433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MFHP
Description: US Surgeon General's family history tool
Study NCT02887937 — intervention group
Intervention type: DRUG
Intervention: Definity
Description: The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
Study NCT02717663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goals
Description: Prescribed goals change daily based on participant's performance
Study NCT02717663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Goals
Description: Prescribed goals remain the same throughout study
Study NCT02717663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed (non-contingent) Incentives
Description: Incentives are provided on bi-monthly basis for participation
Study NCT02717663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Micro-Incentives
Description: Incentives are provided immediately for each goal attained
Study NCT03165539 — intervention group
Intervention type: DEVICE
Intervention: Cerebral oxygen saturation monitoring
Description: Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
Study NCT00614705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 6 mg dose in oral capsule form, once daily for 28 days
Study NCT00614705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule form, once daily for 28 days
Study NCT01432834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laser in situ keratomileusis (LASIK)
Description: During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH \& Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol.
Study NCT01432834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Photorefractive keratectomy (PRK)
Description: The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected.
Study NCT02676856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell microtransplantation-long-term
Description: Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.
Study NCT02676856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell microtransplantation-short-term
Description: Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.
Study NCT02676856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning for CR group
Description: For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
Study NCT02676856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning for Non-CR group
Description: For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
Study NCT05829707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain >4 on the VAS, meperidine 20-30 mg for VAS >or = 4
Study NCT05829707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine bolus analgesia
Description: The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain >4 on the VAS, meperidine 20-30 mg for VAS >or = 4.
Study NCT05829707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine PCA group
Description: The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain >4 on the VAS, and meperidine 20-30 mg for VAS >or = 4.
Study NCT04622033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
Study NCT03166163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azadirachta indica
Description: Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
Study NCT03166163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
Study NCT02868177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Totum-63
Description: Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.